1. Identification of anti-virulence compounds that disrupt quorum-sensing regulated acute and persistent pathogenicity
- Author
-
Biliana Lesic, Valeria Righi, Jianxin He, Laurence G. Rahme, François Lépine, A. Aria Tzika, Arunava Bandyopadhaya, Tomoe Kitao, Damien Maura, Melissa Starkey, Sylvain Milot, Shriners Hospitals for Children [Boston], Department of Microbiology and Immunobiology, Harvard Medical School [Boston] (HMS), Department of Surgery, Harvard Medical School [Boston] (HMS) - Massachusetts General Hospital, Institut Armand Frappier (INRS-IAF), Institut National de la Recherche Scientifique [Québec] (INRS) - Réseau International des Instituts Pasteur (RIIP) - Institut Armand Frappier, Yersinia, Institut Pasteur [Paris], NMR Surgical Laboratory, Department of Surgery, Harvard Medical School [Boston] (HMS) - Massachusetts General Hospital and Shriners Burn Institute, Athinoula A. Martinos Center of Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Starkey, Melissa, Lepine, Francoi, Maura, Damien, Bandyopadhaya, Arunava, Lesic, Biljana, He, Jianxin, Kitao, Tomoe, Righi, Valeria, Milot, Sylvain, Tzika, Aria, Rahme, Laurence, Harvard Medical School [Boston] (HMS)-Massachusetts General Hospital [Boston], Institut National de la Recherche Scientifique [Québec] (INRS)-Réseau International des Instituts Pasteur (RIIP), Massachusetts General Hospital [Boston], and MS and DM were supported by Shriners Postdoctoral Fellowships #8506, #84206 respectively. TK was supported by International Research Fellowshipfrom Uehara Memorial Foundation. LR was supported by Shriners Grant #87700 and #85300, NIH grants R21AI105902 and R56AI063433-06A1 and Cystic Fibrosis Foundation grant CFF#11P0. NERCE/NSRB was funded by U54 AI057159
- Subjects
[SDV]Life Sciences [q-bio] ,Drug resistance ,medicine.disease_cause ,Mice ,Drug Discovery ,Medicine and Health Sciences ,Biology (General) ,Pathogen ,Virulence ,Quorum Sensing ,Drug Resistance, Multiple ,3. Good health ,Bacterial Pathogens ,Anti-Bacterial Agents ,Medical Microbiology ,Pseudomonas aeruginosa ,[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Research Article ,Biotechnology ,Chromatin Immunoprecipitation ,Drug Research and Development ,Multidrug tolerance ,QH301-705.5 ,Immunology ,Biology ,Microbiology ,Pseudomonas Infection ,Antibiotic resistance ,Genetic ,Virology ,Microbial Control ,Anti-Bacterial Agent ,Drug Resistance, Bacterial ,Genetics ,medicine ,Animals ,Pseudomonas Infections ,Molecular Biology ,[SDV.MP] Life Sciences [q-bio]/Microbiology and Parasitology ,Microbial Pathogens ,Pharmacology ,Animal ,Biology and Life Sciences ,RC581-607 ,[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology ,Quorum sensing ,Disease Models, Animal ,Regulon ,Small Molecules ,Parasitology ,[SDV.MP.BAC] Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology ,Immunologic diseases. Allergy - Abstract
Etiological agents of acute, persistent, or relapsing clinical infections are often refractory to antibiotics due to multidrug resistance and/or antibiotic tolerance. Pseudomonas aeruginosa is an opportunistic Gram-negative bacterial pathogen that causes recalcitrant and severe acute chronic and persistent human infections. Here, we target the MvfR-regulated P. aeruginosa quorum sensing (QS) virulence pathway to isolate robust molecules that specifically inhibit infection without affecting bacterial growth or viability to mitigate selective resistance. Using a whole-cell high-throughput screen (HTS) and structure-activity relationship (SAR) analysis, we identify compounds that block the synthesis of both pro-persistence and pro-acute MvfR-dependent signaling molecules. These compounds, which share a benzamide-benzimidazole backbone and are unrelated to previous MvfR-regulon inhibitors, bind the global virulence QS transcriptional regulator, MvfR (PqsR); inhibit the MvfR regulon in multi-drug resistant isolates; are active against P. aeruginosa acute and persistent murine infections; and do not perturb bacterial growth. In addition, they are the first compounds identified to reduce the formation of antibiotic-tolerant persister cells. As such, these molecules provide for the development of next-generation clinical therapeutics to more effectively treat refractory and deleterious bacterial-human infections., Author Summary Antibiotic resistant and tolerant bacterial pathogens are responsible for acute, chronic and persistent human infections recalcitrant to any current treatments. Therefore, there is an urgent need to identify new antimicrobial drugs that will help circumvent the current antibiotic resistance crisis. Bacterial pathogens often develop resistance to antibiotic drugs that target bacterial growth or viability. In contrast, strategies that specifically target virulence pathways non-essential for growth could limit selective resistance, and thus are candidates for the development of next-generation antimicrobial therapeutics. In this study we target the bacterial communication system MvfR (PqsR), which is known to control virulence of the opportunistic bacterial pathogen Pseudomonas aeruginosa. We identified and improved upon new small molecules that effectively silence the MvfR communication system, and as a result block P. aeruginosa virulence both in vitro and in vivo. Moreover, these new compounds are the first known to restrict the ability of bacteria to form antibiotic-tolerant cells and consequently proved to be very effective at preventing persistent infection in a mammalian infection model. Because of their ability to simultaneously block acute and persistent infections, these new molecules may provide a very strong basis for the development of next generation antimicrobials.
- Published
- 2014
- Full Text
- View/download PDF